Learning Hub

< BACK Season's Greetings from iPROLEPSIS Dec 21, 2023 Merry Christmas and Happy New Year! No updates and announcements, simply warmth, joy, health and peace from the iPROLEPSIS consortium to all our community! Thank you for being a part of our journey. merry (1).png merry (1).png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at IEEE-EMBS BSN 2025 Nov 6, 2025 Showcasing iPROLEPSIS at a leading international conference on body sensor research The IEEE-EMBS International Conference on Body Sensor Networks (IEEE-EMBS BSN 2025) took place in Los Angeles, USA, from 3–5 November 2025. The conference brings together researchers, clinicians, and industry representatives working on body sensor technologies and their applications in health and biomedical research. iPROLEPSIS was showcased at the event by project partner PLUX , which hosted a dedicated booth. The project was presented to an international audience, increasing its visibility within the body sensor and digital health research community. IEEE EMBS 2025 2.HEIC IEEE EMBS 2025 1.HEIC IEEE EMBS 2025 3.HEIC IEEE EMBS 2025 2.HEIC 1/3 PREVIOUS NEXT

< BACK The miPROLEPSIS App Now Available for Android Devices on Google Play Store Sep 30, 2024 A data collection tool for the iPROLEPSIS-PDPID study now on Android As of 30 September 2024, the miPROLEPSIS app is available for Android devices on the Google Play Store. The miPROLEPSIS PDPID Study application functions as a data collection tool, utilized during the PDPID study, in order to produce datasets used for model generation and training. The app utilises both continuous and unobtrusive data collection (via bluetooth) from wearable devices, as well as user interactions (questionnaires, reporting etc). miPROLEPSIS - Apps on Google Play 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Games Selected for HiTech 2025 Feb 13, 2025 Transforming Research into Real-World Solutions The iPROLEPSIS consortium partners from FMH/IST-ULisboa are pleased to announce that iPROLEPSIS Games has been selected as one of the 16 teams for the HiTech 2025 Program . HiTech 2025, organised by HiSeedTech , supports research teams in transforming deep tech innovations into market-ready solutions . This selection marks an exciting step forward for iPROLEPSIS Games , reinforcing our commitment to bridging the gap between scientific research and practical applications . 🔗 Read more about the program: HiSeedTech: Programs 1/1 PREVIOUS NEXT

< BACK Insights from the Psoriasispatiënten Nederland Information Afternoon Nov 11, 2024 Reflection on the recent information afternoon for patients with psoriasis and psoriatic arthritis hosted by Psoriasispatiënten Nederland On 9 November 2024, in celebration of World Psoriasis Day , Psoriasispatiënten Nederland (Psoriasis Patients Netherlands) hosted an informative event in Nijkerk (the Netherlands). With over 90 attende es, the event was a great success, offering valuable insights and fostering connections among patients, clinicians, and researchers. The event aimed to offer the latest information on psoriasis and psoriatic arthritis while fostering discussions on treatment options and research advancements. A diverse range of expert presentations and interactive sessions enhanced attendees' understanding and contributed to improving patient care. During breaks, participants had the opportunity to visit several information stands and engage with researchers and specialists. iPROLEPSIS was represented by Jolanda Luime ( Erasmus MC ) , who shared insights into the ongoing research project focused on the prevention and early diagnosis of psoriatic arthritis. The event proved to be an insightful and inspiring day, bringing together a diverse group of patients, researchers, and healthcare professionals. The discussions, networking opportunities, and practical sessions contributed to a deeper understanding of psoriatic arthritis and psoriasis, making it a valuable experience for all involved. Read more: Terugblik op de afgelopen informatiemiddag - Psoriasispatiënten Nederland 1/6 PREVIOUS NEXT

< BACK iPROLEPSIS at Health Data Summit 2025 Feb 12, 2025 Trustworthy AI in Digital Health iPROLEPSIS is excited to join AI-PROGNOSIS and other Horizon Europe research and innovation projects - T RUSTroke, SmartCHANGE, and STRATIFYHF - at the Health Data Summit 2025 in Brussels. Together, these projects will focus on practical approaches for building trustworthy AI-enabled digital health tools aimed at assessing disease risk and progression. During the workshop titled " Trustworthy AI in Digital Health: From Guidelines to Practice" on 19-20 March 2025, iPROLEPSIS will join experts in discussing the importance of ensuring data quality, addressing bias, and applying ethical AI principles in healthcare solutions. The workshop will cover frameworks, methods, and techniques across the AI system development lifecycle, emphasising how to build AI tools that are robust, fair, transparent, and protect privacy. Key discussion topics include: Ensuring data quality and mitigating bias in AI-driven healthcare Applying ethical AI principles throughout AI system development Balancing fairness, privacy, transparency, and robustness The session will be an opportunity for iPROLEPSIS and its partners to contribute to advancing the responsible use of AI in healthcare and discuss solutions for improving digital health tools. Event details: Health Data Summit 2025 Programme details: Summit Programme 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Research on Digital Rheumatology Published in The Lancet eClinicalMedicine May 19, 2025 New Publication Highlights Explainable AI Tools, Digital Biomarkers, and Multimodal Disease Monitoring for PsA A recent paper published in The Lancet eClinicalMedicine presents the iPROLEPSIS initiative as a comprehensive European research effort aimed at transforming the diagnosis and management of psoriatic arthritis (PsA) through digital innovation and patient-centred care . The paper, titled "European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis", outlines how iPROLEPSIS addresses critical gaps in current PsA care by combining real-world data , wearable sensors , and explainable artificial intelligence (xAI) models. Abstract The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients’ interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read the full paper here: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00175-0/fulltext PIIS2589537025001750 .pdf Download PDF • 1.20MB Lancet publication.png Lancet publication.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS joins the YouTube channel Jan 23, 2024 Join Our Digital Journey – Follow iPROLEPSIS on YouTube iPROLEPSIS has officially joined the YouTube community . Follow our YouTube Channel: iPROLEPSIS - YouTube . Join us as we delve into novel digital solutions for psoriatic arthritis. Stay tuned for informative and engaging content! transparent-glass-bubble-with-youtube-logo-inside-it.jpg transparent-glass-bubble-with-youtube-logo-inside-it.jpg 1/1 PREVIOUS NEXT

< BACK Initiation of the iPROLEPSIS-PDPID Study Oct 22, 2024 Initiating Patient Enrollment for Psoriatic Arthritis Research The PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) has officially been initiated. The first patient was enrolled in the Netherlands in early September. The iPROLEPSIS-PDPID study focuses on using smart devices and clinical data to develop AI-driven models for personalised monitoring and flare prediction. This approach aims to empower patients by providing tools to better understand their condition. The study seeks to develop unobtrusive and affordable digital biomarkers capable of detecting changes in disease activity, including flares, and identifying their triggers in patients with psoriatic arthritis (PsA). The study is being conducted in four countries: the Netherlands, the UK, Portugal, and Greece. Patient recruitment is planned to start in the UK by the end of October, with recruitment in Greece and Portugal expected later this year. The miPROLEPSIS phone app is used in this study. The app is installed on patients' smartphones and acts as a data collection tool, which will be used to develop and train algorithms. The app measures physical activity, sleep duration, self-registered flares, and daily records of pain, fatigue, sleep quality, and morning stiffness. Additionally, the Garmin Vivoactive 5 smartwatch is used to collect data on physical activity, heart rate, heart rate variability, and sleep quality. 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented to Eli Lilly in the Netherlands Nov 8, 2023 Presentation to Eli Lilly introduces iPROLEPSIS as the next step in personalised psoriatic arthritis care On the 7th of November 2023, Ilja Tchetverikov from CICERO Rheumatology presented the results and prospects of the DEPAR cohort and introduced iPROLEPSIS clinical studies to the representatives of Eli Lilly company in the Netherlands. DEPAR, Dutch south-west Psoriatic Arthritis Registry, is a registry set up by Cicero Rheumatology, a partnership of rheumatologists working in 15 different hospitals in the south-west of the Netherlands. DEPAR, with the participation of well over 900 patients, supports rheumatologists to gain insight into the treatment and course of psoriatic arthritis. The presentation highlighted iPROLEPSIS as a logical next step in the further development of DEPAR, emphasising the project’s vision and aim to explain psoriatic arthritis inflammation through multi-source data analysis, guiding to a novel personalised digital care ecosystem. Slide1.JPG Slide2.JPG Slide6.JPG Slide1.JPG 1/6 PREVIOUS NEXT

< BACK Patty de Groot Discusses Digital Biomarkers in Rheumatology Podcast Jan 10, 2025 Exploring the Future of Digital Biomarkers in Rheumatology Patty de Groot from Erasmus MC recently appeared on the Digital Rheumatology Network podcast on Spotify, where she shared her insights on the role of digital biomarkers in rheumatology care. In this engaging conversation, Patty discusses the potential of digital tools, including findings from the iPROLEPSIS project, to improve early diagnosis, personalise treatment, and enhance patient care. She also talks about the use of design-thinking approaches to optimise healthcare workflows and the challenges of integrating digital innovations in clinical practice. Listen to the full podcast episode to learn more about how digital biomarkers are transforming rheumatology care and the future of healthcare innovation. 🎧 Listen here 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Presented at the 7th Panhellenic Multidisciplinary Congress of Autoimmune Diseases, Rheumatology & Clinical Immunology Apr 7, 2025 Engaging the clinical community with updates on iPROLEPSIS and ongoing research From 28–30 March 2025, the 7th Panhellenic Multidisciplinary Congress of Autoimmune Diseases, Rheumatology & Clinical Immunology took place in Portaria, Greece. Maria Mytilinaiou , representing the Aristotle University of Thessaloniki (AUTH) , presented an overview of the iPROLEPSIS and HIPPOCRATES projects and ongoing clinical studies. The congress brought together clinicians and researchers from across Greece, offering a valuable opportunity to share insights and strengthen collaboration. 1/3 PREVIOUS NEXT